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The renal arginine vasopressin receptors
and regulation of blood pressure
Jingo KAGEYAMA
Abstract
Arginine vasopressin (AVP) interacts with at least two types of receptors, classified according to
their second messengers. The vasoconstrictive effect on systemic arteries is mediated throgh VI
receptors. The antidiuretic effect of AVP is mediated by V2 receptors located mainly in the renal
collecting ducts. VI receptors are not affected by physiological dose of AVP blood pressure control,
so the biological significance of AVP in blood pressure control is unknown. In the field of
hypertension research, various hypertension animal models have been used. Spontaneouslyhyper-
tensive rats (SHR), DOCA-salt hypertensive rats, Dahl salt-sensitive or Dahl saltresistant rats. SHR
are often used as a model of human essential hypertension, whereas the DOCA model is considered
to be a model of volume dependent hypertension. Relationship between AVP and regulation of
blood pressure was reviewed.
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